Izana Bioscience

Ankylosing spondylitis (AS) is an incurable, painful, progressive type of arthritis where some or all of the joints and bones of the spine fuse together. It usually presents in the second decade of life with symptoms such as back pain and stiffness. Up to 70% of patients with severe AS develop spinal fusion over 10 to 15 years, which significantly reduces mobility and quality of life. It has wide ranging consequences on the lives of patients, affecting the ability to work of more than 50% of sufferers. It is a significant cause of morbidity and treatment options remain limited with a large unmet need in many patients who do not respond to conventional therapy. IZN-101 is a novel new treatment in development for AS, offering patients an alternative approach to current therapies. We are preparing to run a Phase II study of IZN-101, an anti GM-CSF monoclonal antibody in AS. It will take place in the UK, and aims to demonstrate the efficacy of IZN-101 as measured by changes in clinical symptoms, markers of inflammation and MRI appearance of the spine. The trial will be a randomised, double-blind, placebo-controlled study in patients with moderately to severely active AS.
Social Link - Linkedin: http://www. linkedin.com/company /izana-bioscience
Employee Count: 2
Keywords: biotechnology research